AKBA
Akebia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.68
+1.51%Oct 14, 2026, 12:02 UTC
Nicholas Grund resigned as Akebia Therapeutics’ Senior Vice President and Chief Commercial Officer, effective November 6, 2026.
Oct 6, 2026, 12:00 UTC
Akebia Therapeutics announced upcoming presentations of its late-breaking VOICE trial and rare kidney pipeline posters at ASN Kidney Week 2026 in Denver, Colorado, from October 21-25, 2026.
Source:Sep 22, 2026, 12:11 UTC
SCYNEXIS Inc. appointed Steven K. Burke, M.D. to its Board of Directors effective September 18, 2026, with compensation including an annual retainer of $45,000 and equity grants.
Sep 14, 2026, 12:00 UTC
Akebia Therapeutics dosed the first patient in its Phase 2 basket trial of ebribafusp for rare complement-mediated kidney diseases including IgA nephropathy, lupus nephritis and C3 glomerulopathy.
Source:Aug 5, 2026, 22:05 UTC
Akebia Therapeutics reported second-quarter revenue growth for its Vafseo anemia treatment and highlighted an interim clinical result from the VOICE study and progress across its kidney disease pipeline.
Aug 3, 2026, 12:00 UTC
Akebia Therapeutics initiated a Phase 2 basket trial to study ebribafusp, a next-generation complement inhibitor, for rare complement-mediated kidney diseases including IgA nephropathy, lupus nephritis, and C3 glomerulopathy.
Source:Jun 30, 2026, 12:00 UTC
U.S. Renal Care and Akebia Therapeutics announced that the VOICE trial for Vafseo was stopped after an interim analysis showed improved safety outcomes.
Source: